Skip to main content
An official website of the United States government

Radiation Therapy SPORE

Radiation therapy (RT) is used to treat locally advanced cancer in many organ sites, especially primary tumors that are nonresectable. The combination of RT with standard chemotherapeutic agents (chemoRT) has improved clinical outcomes by both controlling local and micrometastatic disease. ChemoRT has become a standard treatment for many locally advanced cancers. However, toxicity to normal tissue and cancer cell resistance mechanisms limit the effectiveness of these combinations. Many pathways for cancer cell radiation resistance have been identified and may now be targeted with new therapeutic agents. The ability of targeted therapies to selectively increase cancer cells', and not normal tissues', sensitivity to chemoRT will improve clinical outcomes. The Molecularly Targeted Radiosensitization of Locally Advanced Cancers SPORE focuses on targeting major mechanisms of radiation resistance in three different locally advanced cancers: pancreatic cancer, glioblastoma, and breast cancer. This is the first thematic SPORE focused on radiation therapy.

University of Michigan Radiation Therapy SPORE

  • Reviewed:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Radiation Therapy SPORE was originally published by the National Cancer Institute.”

Email